Understand your inflammatory bowel disease (crohn's + uc) denial. Build a reviewable appeal.
Upload the denial notice, verify the extracted facts, identify missing evidence, and prepare a package for treating-clinician review. The notice and applicable rules determine the available route and deadline.
The denial notice
Confirm the payer's stated reason, plan language, dates, and review rights from the actual notice.
Facts and evidence
Keep extracted information linked to its source. Unknown facts stay unknown until you or the clinician confirms them.
Route and review
Classify the next step, verify any deadline, and identify what requires treating-clinician review or signature.
Four clear stages.
Upload your denial — and any clinical records you have
Take a photo, scan, or upload PDFs of the denial letter. Adding labs, prior PA letters, or visit notes makes the appeal stronger — but the denial alone is enough to start.
Confirm a few facts
We pre-fill what was extracted. You confirm, correct, or leave it unknown.
We draft your appeal
A source-linked draft and evidence checklist for treating-clinician review.
Your doctor signs and files
We email the letter to you. Your doctor reviews, signs, and submits.
Common questions
Can I appeal a denied insurance claim for Inflammatory bowel disease (Crohn's + UC)?
The denial notice and governing plan or program determine whether and how the decision can be challenged. DenialHelp first classifies the route, then organizes the relevant facts and sources. Filing dates vary and must be verified against the actual notice.
What does DenialHelp cost for a Inflammatory bowel disease (Crohn's + UC) appeal?
$39 for a first-level appeal. Other review levels use the current prices shown on the pricing page. The refund promise concerns the described deliverable, not the insurer's decision.
Who reviews and signs the Inflammatory bowel disease (Crohn's + UC) appeal letter?
The patient's treating physician reviews and signs the appeal letter before it is submitted to the insurer. DenialHelp drafts the letter; the patient and prescribing physician are responsible for submission. We do not file appeals on behalf of patients.
What treatments are covered under Inflammatory bowel disease (Crohn's + UC)?
Humira (adalimumab) SC — CD FDA Feb 2007 / UC FDA Sep 2012 (CLASSIC, ULTRA 1/2), Remicade (infliximab) IV — CD FDA Aug 1998 / UC FDA Sep 2005 (ACCENT-1/2, ACT-1/2), Cimzia (certolizumab pegol) SC — CD-only FDA Apr 2008 (PRECISE-1/2), Simponi (golimumab) SC — UC-only FDA May 2013 (PURSUIT-SC, PURSUIT-Maintenance), Stelara (ustekinumab) IV induction + SC maintenance — CD FDA Sep 2016 / UC FDA Oct 2019 (UNITI-1/2, IM-UNITI, UNIFI), Skyrizi (risankizumab) IV induction + SC maintenance — CD FDA Jun 2022 / UC FDA May 2024 (ADVANCE, MOTIVATE, FORTIFY, INSPIRE, COMMAND), Tremfya (guselkumab) IV induction + SC maintenance — UC FDA Sep 2024 (QUASAR); CD GALAXI program ongoing, Entyvio (vedolizumab) IV — UC + CD FDA May 2014 (GEMINI 1/2/3, VARSITY); SC maintenance FDA Sep 2023
Ready to fight your denial?
Our free pre-payment review runs before checkout. Refund requests made within 7 calendar days of payment are processed automatically; later requests are reviewed under the Terms. A refund policy is not a promise of a payer outcome.